Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | XIAP | P98170 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 4/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALPG | P10696 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | CPA3 | P15088 | 2/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4316458 | 0.83 | CYP1A2 (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL490844 | 0.83 | CYP1A2 (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL4826192 | 0.83 | CYP1A2 (0.61) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL17763412 | 0.83 | CYP1A2 (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL31635698 | 0.82 | ACACB (0.45) | — | |
| SCHEMBL3634087 | 0.82 | ACACB (0.47) | CYP1A2NPC1RAB9A | |
| SCHEMBL5609832 | 0.81 | ALPI (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Bromide SCHEMBL1596942 | 0.81 | CYP1A2 (0.59) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1596941 | 0.81 | CYP1A2 (0.54) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL4283538 | 0.80 | SLC6A2 (0.47) | NPC1RAB9ALMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368001-A1 | SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2024-11-07 | — | — | US | disclosed |
| US-11987506-B2 | Salt recovery solution and processes of use thereof | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2024-05-21 | — | — | US | disclosed |
| US-20230257284-A1 | SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2023-08-17 | — | — | US | disclosed |
| CN-116282078-A | Salt recovery solution and method of using the same | 阿克福特斯技术有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-111225875-B | Salt recovery solution and method of using salt recovery solution | 阿克福特斯技术有限公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20230043356-A1 | A SOLVENT DRYING COMPOSITION AND PROCESSES THEREFOR | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2023-02-09 | — | — | US | disclosed |
| EP-3946712-A1 | A SOLVENT DRYING COMPOSITION AND PROCESSES THERFOR | Aquafortus Technologies Limited (NZ) | 2022-02-09 | — | — | EP | disclosed |
| CN-113891760-A | Solvent drying compositions and related methods | 阿克福特斯技术有限公司 | 2022-01-04 | — | — | CN | disclosed |
| WO-2020204733-A1 | A SOLVENT DRYING COMPOSITION AND PROCESSES THERFOR | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2020-10-08 | — | — | WO | disclosed |
| US-20200308023-A1 | SALT RECOVERY SOLUTION AND PROCESSES OF USE THEREOF | AQUAFORTUS TECHNOLOGIES LIMITED (NZ) | 2020-10-01 | — | — | US | disclosed |
| EP-1214041-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001049323-A1 | COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES | ELI LILLY AND COMPANY (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2000037022-A2 | COMBINATION THERAPY FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2000-06-29 | — | — | WO | disclosed |
| EP-1011670-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 2000-06-28 | — | — | EP | disclosed |
| EP-1007056-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999016453-A1 | METHOD FOR THE TREATMENT OF CYSTIC FIBROSIS | ELI LILLY AND COMPANY (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1999009978-A1 | METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS | ELI LILLY AND COMPANY (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0772596-A4 | INDOLIZINE sPLA2 INHIBITORS | LILLY CO ELI (US) | 1999-01-13 | — | — | EP | disclosed |
| EP-0772596-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996003383-A1 | INDOLIZINE sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043356-A1 | A SOLVENT DRYING COMPOSITION AND PROCESSES THEREFOR | AQP1, AQP4, NOTUM | ALPI 4635/4885PKM 2856/4885PTGS1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.